Loading organizations...
§ Private Profile · Boston, MA, USA
ZappRx is a technology company.
ZappRx delivers a digital health platform designed to streamline the complex process of managing specialty medications. The company's technology facilitates a collaborative online environment that connects patients, prescribing physicians, and pharmacies, enabling more efficient handling of prescriptions and critical prior authorizations. This integrated approach aims to reduce administrative burdens and accelerate access to essential treatments for individuals with chronic or rare conditions.
The company was established in 2012 by founder Zoe Barry, whose experience as a former Athenahealth executive provided her with deep insight into healthcare inefficiencies. Barry recognized the significant challenges and delays inherent in the traditional specialty prescription workflow. This understanding fueled her vision to develop a centralized, secure system that could simplify ordering, improve communication, and ultimately enhance patient care.
ZappRx serves the ecosystem of stakeholders involved in specialty drug therapy, including healthcare providers seeking to expedite prescriptions and patients requiring timely access to their medications. The platform’s overarching mission is to modernize and simplify specialty medication management, fostering a more connected and responsive healthcare journey. Its forward-looking vision centers on creating a more accessible and navigable path for patients requiring specialized treatments.
ZappRx has raised $40.0M across 3 funding rounds.
ZappRx has raised $40.0M in total across 3 funding rounds.
ZappRx has raised $40.0M in total across 3 funding rounds.
ZappRx's investors include Qiming Venture Partners USA, 2048 Ventures, Apollo Health Ventures, BDC Venture Capital, Founder Collective, Clark Landry, Jeff Seibert, Google Ventures, SR One, Jens Eckstein, Atlas Ventures, Life Sciences Angel Network.
ZappRx has raised $40.0M across 3 funding rounds. Most recently, it raised $25.0M Series B in April 2017.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2017 | $25M Series B | Qiming Venture Partners USA | 2048 Ventures, Apollo Health Ventures, BDC Venture Capital, Founder Collective, Clark Landry, Jeff Seibert, GV, SR ONE | Announced |
| Apr 1, 2015 | $14M Series A | Jens Eckstein | Apollo Health Ventures, BDC Venture Capital, Atlas Ventures | Announced |
| Sep 1, 2013 | $1M Seed | Atlas Ventures, Life Sciences Angel Network | LearnLaunch Accelerator, Apollo Health Ventures, BDC Venture Capital, David Hamamoto, George Kassabgi, Hakan Satiroglu, James Glimm, Sean Trigony, Terry Meguid, Will Cowen | Announced |
ZappRx was a digital health technology company that built a cloud-based platform streamlining the prescription and fulfillment process for specialty medications, particularly for complex conditions like rare diseases in pulmonary and respiratory areas.[1][2][3] It served patients, physicians, pharmacists, and biopharma partners such as Bayer, Genentech, and Teva by automating administrative tasks like electronic prior authorizations and REMS documentation, reducing delays in treatment access.[1][2][5] The platform solved the burdensome, paper-heavy processes that slowed specialty drug delivery, enabling faster medicine access while providing real-time data transparency for providers and pharma companies; ZappRx raised $32.6M–$42M before being acquired by Allscripts (now Veradigm) in June 2019.[1][2]
ZappRx was founded in 2012 in Boston, Massachusetts, by Zoe Barry, inspired by a family member's struggle to access critical medication during illness.[3] Barry, as CEO, developed the idea for a software platform to modernize specialty prescriptions after recognizing gaps in the traditional, inefficient system reliant on faxes and manual checks.[2][3][4] Early traction came from high-profile health system customers and academic medical centers, with the company securing over $40M from investors including Google Ventures, GlaxoSmithKline, and Qiming Venture Partners; a pivotal 2015 Harvard Business School case highlighted Barry's business model debates between exclusive pharma partnerships and an open platform monetized via data sales.[1][3][4]
ZappRx rode the digital health wave transforming specialty pharmacy amid rising demand for high-cost, complex drugs like those for rare diseases, where prior authorizations often delayed care by weeks.[2][4] Timing aligned with EHR integration needs and payer pressures, positioning it against competitors like Phil, Capsule, and Blink Health in e-prescribing and medication access.[1] Market forces favoring it included biopharma's push for patient adherence data and providers' frustration with legacy fax-based systems; its 2019 acquisition by Allscripts bolstered Veradigm's e-prescribing for payers and life sciences, influencing ecosystem-wide efficiency in a space disrupted by Amazon's PillPack and health IT consolidation.[2][7]
Post-acquisition, ZappRx's technology augmented Veradigm's platform, likely enhancing specialty prescribing within Allscripts' EHR ecosystem amid ongoing digital health innovation.[2][7] Trends like AI-driven authorizations and value-based care will shape its legacy, potentially expanding to broader therapeutics as data analytics demand grows. Its influence endures in streamlined specialty workflows, proving a prescient model for collaborative health tech that accelerated patient access in a fragmented market.